Topical phospho-sulindac (OXT-328) is effective in the treatment of non-melanoma skin cancer

@article{Cheng2012TopicalP,
  title={Topical phospho-sulindac (OXT-328) is effective in the treatment of non-melanoma skin cancer},
  author={K. W. Cheng and G. Mattheolabakis and C. Wong and N. Ouyang and Liqun Huang and P. Constantinides and B. Rigas},
  journal={International Journal of Oncology},
  year={2012},
  volume={41},
  pages={1199 - 1203}
}
Phospho-sulindac (P-S, OXT-328), a novel sulindac derivative, has shown superior anticancer efficacy and safety compared to sulindac. In this study, we investigated the efficacy of topical P-S hydrogel in the treatment of non-melanoma skin cancer in preclinical models. P-S is a potent inhibitor of A431 epidermoid carcinoma in vitro and achieves this effect by inhibiting cell proliferation and inducing apoptosis. The anticancer efficacy of topical and oral P-S was further evaluated in mice… Expand
The ocular pharmacokinetics and biodistribution of phospho‐sulindac (OXT‐328) formulated in nanoparticles: Enhanced and targeted tissue drug delivery
Phospho-NSAIDs Have Enhanced Efficacy in Mice Lacking Plasma Carboxylesterase: Implications for their Clinical Pharmacology
Nanoemulsions and nanoparticles for non-melanoma skin cancer: effects of lipid materials
NSAID-induced corneal melt: Clinical importance, pathogenesis and risk mitigation.
...
1
2
...

References

SHOWING 1-10 OF 24 REFERENCES
Phospho-sulindac (OXT-328), a novel sulindac derivative, is safe and effective in colon cancer prevention in mice.
Phospho-Sulindac (OXT-328) Combined with Difluoromethylornithine Prevents Colon Cancer in Mice
Chemotherapeutic properties of phospho-nonsteroidal anti-inflammatory drugs, a new class of anticancer compounds.
Phospho-sulindac (OXT-922) inhibits the growth of human colon cancer cell lines: a redox/polyamine-dependent effect.
Carboxylesterases 1 and 2 Hydrolyze Phospho-Nonsteroidal Anti-Inflammatory Drugs: Relevance to Their Pharmacological Activity
Phospho-Ibuprofen (MDC-917) Is a Novel Agent against Colon Cancer: Efficacy, Metabolism, and Pharmacokinetics in Mouse Models
  • G. Xie, Y. Sun, +5 authors B. Rigas
  • Chemistry, Medicine
  • Journal of Pharmacology and Experimental Therapeutics
  • 2011
Chemoprevention of Nonmelanoma Skin Cancer With Celecoxib: A Randomized, Double-Blind, Placebo-Controlled Trial
...
1
2
3
...